InMed Pharmaceuticals Inc. SEC filings INM
InMed Pharmaceuticals Inc. has 514 filings in SEC EDGAR's recent list, going back to Jan 17, 2018. Its latest annual report, Form 10-K, was filed on Sep 9, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Nov 2, 2026 | — |
| 425 | Filing | Oct 27, 2026 | — |
| EFFECT | Filing | Oct 1, 2026 | — |
| 425 | Form 425 | Sep 9, 2026 | — |
| 425 | Form 425 | Jul 22, 2026 | — |
| 425 | Current report | Jul 22, 2026 | — |
| 425 | Form 425 | Jul 20, 2026 | — |
| 425 | Current report | Jul 10, 2026 | — |
| 425 | Current report | May 19, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| CORRESP | Letter to the SEC | Mar 26, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2026 | — |
| EFFECT | Filing | Aug 1, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| CORRESP | Letter to the SEC | Jul 14, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2025 | — |
| EFFECT | Filing | Dec 31, 2024 | — |
| CORRESP | Letter to the SEC | Dec 30, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2024 | — |
| EFFECT | Filing | Nov 13, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2023 | — |
| NT 10-K | Notification of late filing | Sep 29, 2023 | Jun 30, 2023 |
| NT 10-Q | Notification of late filing | Feb 10, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Dec 14, 2022 | — |
| CORRESP | Letter to the SEC | Dec 12, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2022 | — |
| D | Filing | Dec 6, 2022 | — |
| EFFECT | Filing | Oct 18, 2022 | — |
| CORRESP | Letter to the SEC | Oct 14, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2022 | — |
| EFFECT | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Oct 7, 2022 | — |
| EFFECT | Filing | Jun 29, 2022 | — |
| CORRESP | Letter to the SEC | Jun 27, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2022 | — |
| D | Filing | Jun 8, 2022 | — |
| EFFECT | Filing | Apr 18, 2022 | — |
| CORRESP | Letter to the SEC | Apr 14, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2022 | — |
| EFFECT | Filing | Feb 11, 2022 | — |
| EFFECT | Filing | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 10, 2022 | — |
| CORRESP | Letter to the SEC | Feb 9, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2022 | — |
| D | Filing | Oct 28, 2021 | — |
| EFFECT | Filing | Jul 22, 2021 | — |
| CORRESP | Letter to the SEC | Jul 19, 2021 | — |
| CORRESP | Letter to the SEC | Jul 19, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2021 | — |
| D | Filing | Jul 19, 2021 | — |
| EFFECT | Filing | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 11, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2021 | — |
| EFFECT | Filing | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CERT | Filing | Nov 6, 2020 | — |
| CORRESP | Letter to the SEC | Nov 5, 2020 | — |
| CORRESP | Letter to the SEC | Nov 5, 2020 | — |
| 8-A12B | Filing | Nov 5, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2020 | — |
| CORRESP | Letter to the SEC | Oct 8, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 21, 2020 | — |
| CORRESP | Letter to the SEC | Jul 20, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2020 | — |
| DRSLTR | Filing | Jun 19, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2020 | — |
| DRS/A | Filing | May 27, 2020 | — |
| DRSLTR | Filing | May 26, 2020 | — |
| UPLOAD | Letter from the SEC | May 12, 2020 | — |
| DRS | Filing | Apr 13, 2020 | — |
| D | Filing | Jan 17, 2018 | — |
Showing 82 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INM (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1728328
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.